Company Description
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally.
It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries.
It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications.
The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.
COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 1990 |
| IPO Date | Jul 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | Anna Biehn |
Contact Details
Address: 222 Bay Street, Suite 3000 Toronto, ON M5K 1E7 Canada | |
| Website | cosciensbio.com |
Stock Details
| Ticker Symbol | CSCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001113423 |
| CUSIP Number | 22112H101 |
| ISIN Number | CA22112H1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Anna Elizabeth Biehn | Chief Executive Officer |
| Giuliano La Fratta | Senior Vice President of Finance and Chief Financial Officer |
| Michel Regnier P. Eng. | Senior Vice President of Technical operations, MD of Ceapro Inc. and Chief Technology Officer |
| Dr. Michael Teifel Ph.D. | Senior Vice President of GmbH and Chief Scientific Officer |
| Dr. Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain and Head of Production |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 11, 2025 | SCHEDULE 13D/A | Filing |
| Jun 9, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 20, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 13, 2025 | 6-K | Report of foreign issuer |
| May 2, 2025 | 6-K | Report of foreign issuer |
| Apr 14, 2025 | 6-K | Report of foreign issuer |